Clinically relevant biomarker strategies in drug development

In this interview, NewsMedical speaks with Dr. Justin Devine and Dr. Nicholas Woudberg about biomarkers, their importance for drug development as well as the potential they have when it comes to machine learning.

Related Keywords

Maria Osipova , Justin Devine , Janet Woodcock , Nicholas Woudberg , Wide Association , University Of Cape Town , Pfizer , Nicholas Woudber Justin Devinesynexa Life Sciences , Synexa Life Sciences , Founder Of Synexa Life Sciences , Synexa Life Sciences Bvjan , Sponsored Content , Nicholas Woudber , Justin Devinesynexa Life , Nature Reviews Drug , Genome Wide Association , Cape Town , Biomarker , Arthritis , Artificial Intelligence , Rain , Dancer , D4 , Fell , Central Nervous System , Clinical Diagnostics , Clinical Trial , Ytokines , Ytometry , Iagnostic , Iagnostics , Doctor , Drug Discovery , Drugs , Efficacy , Exosomes , Flow Cytometry , Gene , Enetic , Enome , Heart , Heart Rate , Shiv , Immune System , Ipidology , Machine Learning , Medicine , Nervous System , Ncology , Mh , Harmacology , Research , Rheumatoid Arthritis , Septic Shock , Humor ,